Weighted Average Number of Shares Outstanding, Basic of Seres Therapeutics, Inc. from Q3 2020 to Q3 2025

Taxonomy & unit
us-gaap: shares
Description
Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.
Summary
Seres Therapeutics, Inc. quarterly/annual Weighted Average Number of Shares Outstanding, Basic history and change rate from Q3 2020 to Q3 2025.
  • Seres Therapeutics, Inc. Weighted Average Number of Shares Outstanding, Basic for the quarter ending September 30, 2025 was 8.76M shares, a 14.8% increase year-over-year.
  • Seres Therapeutics, Inc. annual Weighted Average Number of Shares Outstanding, Basic for 2024 was 155M shares, a 21.4% increase from 2023.
  • Seres Therapeutics, Inc. annual Weighted Average Number of Shares Outstanding, Basic for 2023 was 128M shares, a 18.4% increase from 2022.
  • Seres Therapeutics, Inc. annual Weighted Average Number of Shares Outstanding, Basic for 2022 was 108M shares, a 17.9% increase from 2021.
Weighted Average Number of Shares Outstanding, Basic, Quarterly (shares)
Weighted Average Number of Shares Outstanding, Basic, YoY Quarterly Change (%)
Weighted Average Number of Shares Outstanding, Basic, Annual (shares)
Weighted Average Number of Shares Outstanding, Basic, YoY Annual Change (%)

Seres Therapeutics, Inc. Quarterly Weighted Average Number of Shares Outstanding, Basic (shares)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 8.76M +1.13M +14.8% Jul 1, 2025 Sep 30, 2025 10-Q 2025-11-05
Q2 2025 8.74M +1.17M +15.4% Apr 1, 2025 Jun 30, 2025 10-Q 2025-08-06
Q1 2025 8.7M +1.4M +19.1% Jan 1, 2025 Mar 31, 2025 10-Q 2025-05-07
Q4 2024 155M +27.4M +21.4% Oct 1, 2024 Dec 31, 2024 10-K 2025-03-13
Q3 2024 7.63M -121M -94.1% Jul 1, 2024 Sep 30, 2024 10-Q 2025-11-05
Q2 2024 7.58M -120M -94.1% Apr 1, 2024 Jun 30, 2024 10-Q 2025-08-06
Q1 2024 7.31M -119M -94.2% Jan 1, 2024 Mar 31, 2024 10-Q 2025-05-07
Q4 2023 128M +19.9M +18.4% Oct 1, 2023 Dec 31, 2023 10-K 2025-03-13
Q3 2023 128M +5.76M +4.7% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-13
Q2 2023 128M +35.5M +38.4% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-13
Q1 2023 126M +33.7M +36.6% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-08
Q4 2022 108M +16.4M +17.9% Oct 1, 2022 Dec 31, 2022 10-K 2025-03-13
Q3 2022 123M +30.8M +33.5% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-02
Q2 2022 92.3M +596K +0.65% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-08
Q1 2022 92.2M +637K +0.7% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-09
Q4 2021 91.7M Oct 1, 2021 Dec 31, 2021 10-K 2024-03-05
Q3 2021 91.8M +8.23M +9.85% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-02
Q2 2021 91.7M Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-03
Q1 2021 91.5M Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-04
Q3 2020 83.5M Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-10

Seres Therapeutics, Inc. Annual Weighted Average Number of Shares Outstanding, Basic (shares)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 155M +27.4M +21.4% Jan 1, 2024 Dec 31, 2024 10-K 2025-03-13
2023 128M +19.9M +18.4% Jan 1, 2023 Dec 31, 2023 10-K 2025-03-13
2022 108M +16.4M +17.9% Jan 1, 2022 Dec 31, 2022 10-K 2025-03-13
2021 91.7M +11.9M +14.9% Jan 1, 2021 Dec 31, 2021 10-K 2024-03-05
2020 79.8M Jan 1, 2020 Dec 31, 2020 10-K 2023-03-07
* An asterisk sign (*) next to the value indicates that the value is likely invalid.